Pembrolizumab是抗程序性死亡分子1（programmed death-1，PD-1）的单克隆抗体，可与PD-1结合，抑制PD-1与其配体结合，从而激发机体的抗肿瘤作用。在多项临床试验中，Pembrolizumab能显著延长黑色素瘤患者的生存期，因而被美国FDA批准用于治疗晚期不可切除或已转移的恶性黑色素瘤。此文对Pembrolizumab治疗恶性黑色素瘤的研究进展做一综述。

 Pembrolizumab is a monoclonal antibody against programmed death-1. It can inhibit the binding of programmed death-1 with its ligands, then stimulate anti-tumor effect in the body. Pembrolizumab significantly prolonged the survival of patients with malignant melanoma in several clinical trials and was approved by the US FDA for the treatment of unresectable or metastatic melanoma. In this paper, the research progress of Pembrolizumab in treatment of malignant melanoma is reviewed.